McKesson to Acquire Precision Medicine Group for $2.25 Billion to Boost Life Sciences

Key Facts

In a move reflecting strategic expansion into high-margin healthcare sectors, McKesson Corp. has announced an agreement to acquire Precision Medicine Group. The deal, valued at approximately $2.25 billion, involves the transfer of ownership from a Blackstone portfolio company to McKesson. According to reports, Centerview Partners and Simpson Thacher advised Precision Medicine on the transaction, while Davis Polk provided legal counsel to McKesson.

This acquisition occurs as major pharmaceutical distributors pivot toward specialized medical services to drive growth. Per market data, McKesson (MCK) shares closed at $873.79 on August 24, 2026, while Blackstone (BX) shares finished at $143.64 on the same date. The $2.25 billion valuation underscores sustained M&A momentum within the life sciences industry, as mega-cap firms seek to integrate advanced precision medicine capabilities into their existing platforms.

Investors are currently monitoring price levels following the announcement, with MCK recording a day high of $875.64 and a low of $859.75 as of the August 24, 2026 close. Looking ahead, traders are focusing on the upcoming release of the FOMC Minutes later today, which may influence broader market sentiment and financing conditions for future corporate acquisitions.